Sunday, July 15, 2018 1:39:38 PM
But just in case it IS definitive....
I think the agreement is stripped of any potential arbitrary interpretations regarding the P2b test with this:
"“Successful Phase 2b” means that the Company’s Phase 2b trial of Prurisol on psoriasis has met its primary end point, which means a statistically significant increase (p<0.05) in the proportion of patients achieving at least a 75% reduction from baseline in PASI score (PASI75) while receiving Prurisol compared to those receiving placebo at the end of 12 weeks."
There's an itsy bitsy bit of wonkiness in the BTD milestone in that it is achieved "on or before the second Business Day after the Company announces the Break-through Designation" versus the date of "the granting by the U.S. Food and Drug Administration of the Company’s request for Breakthrough Therapy Designation".
I think that the BD Agreement, in spite of the specifics regarding a "double-digits millions of dollars" upfront payment and the understanding that the partner will handle "the conducting and funding of clinical trials aiming towards the filing of an NDA" for B-OM, may be the item most susceptible to interpretation given the way it is written. For example we again see timing based on "the second Business Day after the Company announces the BD Agreement"...not the signing of the agreement or the receipt of the "up-front" payment. I'd like to see that date tied to a more specific event. We see things like Letters of Intent in situations like this...would that meet the BD Agreement definition to the satisfaction of Aspire?
But can it core A apple?
Yes Ralph, of course it can core A apple.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM